Generic Name: glycopyrrolate (inhalation) (GLYE koe PIR oh late)
Brand Name: Seebri Neohaler
What is glycopyrrolate inhalation?
Glycopyrrolate is an anticholinergic that works by relaxing muscles in the airways to improve breathing.
Glycopyrrolate is used as an inhaled medication to prevent airflow obstruction or bronchospasm in people with COPD (chronic obstructive pulmonary disease), including bronchitis and emphysema.
Glycopyrrolate may also be used for purposes not listed in this medication guide.
What is the most important information I should know about glycopyrrolate inhalation?
Follow all directions on your medicine label and package. Tell each of your healthcare providers about all your medical conditions, allergies, and all medicines you use.
What should I discuss with my healthcare provider before using glycopyrrolate inhalation?
You should not use this medicine if you are allergic to glycopyrrolate.
To make sure glycopyrrolate inhalation is safe for you, tell your doctor if you have:
bladder obstruction or other urination problems;
enlarged prostate; or
It is not known whether this medicine will harm an unborn baby. Tell your doctor if you are pregnant or if you become pregnant while using glycopyrrolate inhalation.
It is not known whether glycopyrrolate inhalation passes into breast milk or if it could harm a nursing baby. You should not breast-feed while using this medicine.
Glycopyrrolate inhalation is not approved for use by anyone younger than 18 years old.
How should I use glycopyrrolate inhalation?
Follow all directions on your prescription label. Do not use this medicine in larger or smaller amounts or for longer than recommended.
Glycopyrrolate inhalation powder (Seebri Neohaler) is packaged in capsules that come with a special inhaler device. Each time you use the medicine, load a capsule into the device and click the mouthpiece closed. Push the buttons on the sides of the device to pierce the capsule and release the medicine into the inhalation chamber. Make sure to release the buttons before inhaling the medicine.
The usual dose of this medicine is 1 capsule twice daily. Follow your doctor's dosing instructions very carefully.
Do not swallow the Seebri capsule or place it in your mouth. The capsule is for use only with the Neohaler inhalation device.
Read all patient information, medication guides, and instruction sheets provided to you. Ask your doctor or pharmacist if you have any questions.
Use this medicine at the same time each day, even if you feel well.
Glycopyrrolate inhalation is not a rescue medicine. It will not work fast enough to treat a bronchospasm attack. Use only a fast-acting inhalation medicine for a sudden attack. Tell your doctor if any of your medicines seem to stop working as well in controlling your COPD.
Seek medical attention if your breathing problems do not improve, or if your symptoms get worse quickly.
Use glycopyrrolate inhalation regularly to get the most benefit. Get your prescription refilled before you run out of medicine completely. Always use the new Neohaler device that comes with this medicine.
You should not stop using this medicine unless your doctor tells you to. Stopping suddenly may make your condition worse.
Store at room temperature away from moisture and heat. Keep the capsules in the blister pack until it is time for your dose. Remove only one capsule each time you use the medicine. Do not push a capsule through the foil or you may damage the capsule.
What happens if I miss a dose?
Use the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not use extra medicine to make up the missed dose.
What happens if I overdose?
Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.
Overdose symptoms may include blurred vision, eye pain, nausea, vomiting, trouble urinating, or severe dizziness.
What should I avoid while using glycopyrrolate inhalation?
Follow your doctor's instructions about any restrictions on food, beverages, or activity.
Glycopyrrolate inhalation side effects
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have:
wheezing, choking, or other breathing problems after using this medicine;
blurred vision, tunnel vision, eye pain or redness, seeing halos around lights;
nausea, vomiting; or
painful or difficult urination, little or no urination.
Common side effects may include:
cold symptoms such as stuffy nose, sneezing, sore throat.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
See also: Side effects (in more detail)
Glycopyrrolate dosing information
Usual Adult Dose for Anesthesia:
Preanesthetic (reduction of secretions): 0.004 mg (0.02 mL)/kg IM 30 to 60 minutes prior to the anticipated time of induction of anesthesia or at the time the preanesthetic narcotic and/or sedative are administered.
Intraoperative: 0.1 mg (0.5 mL) IV repeated as needed every 2 to 3 minutes.
Reversal of neuromuscular blockade: 0.2 mg (1.0 mL) IV for each 1.0 mg of neostigmine or 5 mg of pyridostigmine.
Reversal of bradycardia, vagal reflexes (intraoperative): 0.1 mg IV repeated as needed at 2 to 3 minute intervals.
Usual Adult Dose for Peptic Ulcer:
Parenteral: 0.1 mg (0.5 mL) IV or IM every 4 hours, 3 to 4 times daily. If a more profound effect is required the dose may be increased to 0.2 mg (1 mL).
1 mg oral tablet:
Initial dose: 1 mg orally 3 times daily or 1 mg in the morning, 1 mg in the early afternoon, and 2 mg at bedtime.
Maintenance dose: 1 mg orally twice daily to a maximum of 8 mg per day.
2 mg oral tablet: 2 mg orally 2 to 3 times daily to a maximum of 8 mg per day.
1.5 mg oral tablet: Used to provide intermediate titration doses based on patient response.
Usual Pediatric Dose for Anesthesia:
Preanesthetic: 0.004 mg (0.02 mL)/kg IM 30 to 60 minutes prior to the anticipated time of induction of anesthesia or at the time the preanesthetic narcotic and/or sedative are administered. Children under 2 years of age may require up to 0.009 mg (0.45 mL)/kg.
Intraoperative: 0.004 mg (0.02 mL)/kg IV not to exceed 0.1 mg (0.5 mL) in a single dose, repeated as needed every 2 to 3 minutes.
Reversal of neuromuscular blockade: 0.4 mg (2 mL)/kg IV for each 1 mg of neostigmine or 5 mg of pyridostigmine.
Reversal of bradycardia, vagal reflexes (intraoperative): 4 mcg/kg/dose IV (maximum dose: 100 mcg/dose) at 2 to 3 minute intervals.
Usual Pediatric Dose for Excessive Salivation:
3 years to 16 years with neurologic conditions associated with problem drooling:
Initiate dosing at 0.02 mg/kg orally three times daily and titrate in increments of 0.02 mg/kg every 5 to 7 days, based on therapeutic response and adverse reactions. Maximum recommended dose is 0.1 mg/kg three times daily, not to exceed 1.5 to 3 mg per dose based upon weight. Administer at least one hour before or two hours after meals.
What other drugs will affect glycopyrrolate inhalation?
Tell your doctor about all your current medicines and any you start or stop using, especially:
a bronchodilator such as aclidinium, ipratropium, tiotropium, or umeclidinium;
cold or allergy medicine that contains an antihistamine;
medication to treat excess stomach acid, stomach ulcer, motion sickness, or irritable bowel syndrome;
medicine for overactive bladder or urination problems;
medication for Parkinson's disease;
a beta-blocker--atenolol, metoprolol, propranolol, and others; or
an MAO inhibitor--isocarboxazid, linezolid, phenelzine, rasagiline, selegiline, tranylcypromine, and others.
This list is not complete. Other drugs may interact with glycopyrrolate inhalation, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.
More about glycopyrrolate
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- 0 Reviews – Add your own review/rating
- Drug class: anticholinergics/antispasmodics
- Glycopyrrolate solution
- Glycopyrrolate tablets
- Glycopyrrolate (Advanced Reading)
- Glycopyrrolate Inhalation (Advanced Reading)
Related treatment guides
Where can I get more information?
- Your pharmacist can provide more information about glycopyrrolate inhalation.
- Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.
- Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 1996-2012 Cerner Multum, Inc. Version: 1.01.
Date modified: March 15, 2017
Last reviewed: February 02, 2016